scispace - formally typeset
Search or ask a question
Institution

Rhône-Poulenc

About: Rhône-Poulenc is a based out in . It is known for research contribution in the topics: Alkyl & Catalysis. The organization has 8909 authors who have published 8934 publications receiving 182241 citations. The organization is also known as: Rhone-Poulenc.


Papers
More filters
Journal Article
TL;DR: Six optimal sampling strategies with one to six sampling times were computed, based on the D-optimality theory, using population pharmacokinetic parameters estimated from a large pharmacokinetics database of 547 patients treated in previous Phase II studies and clearance was found to be well estimated when at least two samples were taken.
Abstract: Docetaxel activity has been documented in many solid tumors, including metastatic breast cancer and non-small cell lung cancer. However, as clinical studies in other tumor types are now being conducted, the validation of an optimal sampling strategy would allow the performance of pharmacokinetics/pharmacodynamics studies with minimum inconvenience for the patient. Six optimal sampling strategies with one to six sampling times were computed, based on the D-optimality theory, using population pharmacokinetic parameters estimated from a large pharmacokinetic database of 547 patients treated in previous Phase II studies. Validation of these sampling strategies was performed on a set of 35 patients, from two Phase I studies, who received docetaxel as a 1-h infusion at doses ranging from 50 to 100 mg/m2. Validation consisted of comparing clearance assessed by maximum likelihood estimation obtained using complete plasma concentration-time data (considered as the reference) and clearance determined by Bayesian estimation with an optimal design. For all of the optimal sampling strategies tested, clearance was found to be well estimated when at least two samples were taken. Bayesian estimation with two measured levels (at the end of infusion and at 6 h after the start of infusion) can be selected, because it allows adequate estimation of clearance with a nonsignificant bias of +1.37% and a precision of 12.3%.

48 citations

Patent
21 Feb 1991
TL;DR: The rare earth values contained in an aqueous solution of the nitrates of at least two rare earth elements are conveniently separated by first liquid/liquid extracting such nitrate solution with a liquid organic phase containing at least 2 P(O)R 1 R 2 R 3 /P(O 4 R 5 R 6 organophosphorus extractants.
Abstract: The rare earth values contained in an aqueous solution of the nitrates of at least two rare earth elements are conveniently separated by first liquid/liquid extracting such aqueous nitrate solution with a liquid organic phase containing at least two P(O)R 1 R 2 R 3 /P(O)R 4 R 5 R 6 organophosphorus extractants.

48 citations

Patent
10 Feb 1997
TL;DR: In this article, a sale unit for the parenteral application of liquid pharmaceutical products by the user is described, whereby the unit comprises at least one cannula, a device to emit a given liquid amount of the pharmaceutical product in single doses, as well as one vessel filled with the pharmaceutical products, the vessel being arranged within the device and emptied by means of the device.
Abstract: A sale unit for the parenteral application of liquid pharmaceutical products by the user is described, whereby the unit comprises at least one cannula, a device to emit a given liquid amount of the pharmaceutical product in single doses, as well as at least one vessel filled with the pharmaceutical product, the vessel being arranged within the device and emptied in single doses by means of the device, and whereby each single dose corresponds to the given liquid amount of the pharmaceutical product.

47 citations

Journal ArticleDOI
TL;DR: Data suggest that deregulated gax expression induces first cell cycle arrest and then apoptosis in the vascular smooth muscle cells that contribute to the neointimal layer, suggesting the efficacy of this therapeutic strategy appears to result from the ability of the gax transcriptional regulator to modulate multiple cellular responses.
Abstract: Adenovirus-mediated gene delivery in animal models of vascular injury has provided insights into the mechanisms underlying vessel wall pathologies. We have previously demonstrated that overexpression of the Gax transcription factor inhibits neointimal formation in rat and rabbit models of arterial injury. Here, we evaluate potential mechanisms for the reduction in stenotic lesion size due to Gax overexpression. At 3, 7 and 14 days after injury the Ad-Gax-infected arteries displayed a marked decrease in medial vascular smooth muscle cell number (3 days, 54% reduction P < 0.01; 7 days, 41% reduction P < 0.003; 14 days, 49% reduction P < 0.02). At 3 days after injury, PCNA expression was attenuated in the Ad-Gax-treated vessels compared with control vessels (65% reduction P < 0.02), indicating a reduction in cellular proliferation. At 7 days and 14 days after injury Ad-Gax-infected arteries exhibited elevated number of TUNEL-positive medial VSMCs compared with control-treated arteries (7 days, 9.2-fold increase P < 0.03; 14 days, 17.2-fold increase P < 0.03), indicating an induction of apoptotic cell death. These data suggest that deregulated Gax expression induces first cell cycle arrest and then apoptosis in the vascular smooth muscle cells that contribute to the neointimal layer. Therefore, the efficacy of this therapeutic strategy appears to result from the ability of the Gax transcriptional regulator to modulate multiple cellular responses.

47 citations

Journal ArticleDOI
TL;DR: In this article, tertiary amines containing one or more N-benzyl protecting groups with aqueous ceric ammonium nitrate were treated for clean N-debenzylation to afford the corresponding secondary amine.

47 citations


Authors

Showing all 8909 results

NameH-indexPapersCitations
Bart Staels15282486638
Joseph Schlessinger15049298862
Jean-Marie Lehn123105484616
Angus C. Nairn11846944330
Allan I. Basbaum11435555532
Patrick Couvreur11167856735
Joël Vandekerckhove10745238241
Jules A. Hoffmann10624443596
Johan Richard9549925915
Jacques Mallet8140824502
Roland Douce8028418239
David Givol8026020057
Jean-Antoine Girault7724619592
Michel Perricaudet7629620063
Jean-Marie Basset7573723390
Network Information
Related Institutions (5)
Merck & Co.
48K papers, 1.9M citations

89% related

Bristol-Myers Squibb
21K papers, 932.5K citations

88% related

GlaxoSmithKline
21.1K papers, 1.1M citations

87% related

Novartis
50.5K papers, 1.9M citations

87% related

Eli Lilly and Company
22.8K papers, 946.7K citations

87% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
20201
20161
20119
201024
20095
20081